UnknownPhase 2/3

Sildenafil and Uteroplacental Perfusion

Iran70 participantsStarted 2008-06

Plain-language summary

The purpose of this study is to determine whether sildenafil is effective and safe in the treatment of fetal growth restriction.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * FGR pregnancies in 24-37 weeks of GA Exclusion Criteria: * vasodilator agents usage * history of cardiovascular morbidity specially of right heart side * drug or alcohol abusers * systolic BP more than 210 mm Hg or diastolic BP more than 120 mm Hg

What they're measuring

Uteroplacental Perfusion

Timeframe: 2 hours after sildenafil ingestion

Trial details

NCT IDNCT01107782

SponsorTehran University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-06

Contact for this trial

sayedeh afagh hosseini, M.D.

+989188111670 afahoss@yahoo.com

View on ClinicalTrials.gov More Fetal Growth Retardation trials